You just read:

Soligenix Announces Initiation of its Pivotal Phase 3 Clinical Trial of SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma

News provided by

Soligenix, Inc.

14 Dec, 2015, 07:00 ET